Abstract
Neurodegenerative disease, for instance, Parkinson’s disease (PD), is associated with substantia nigra dopaminergic neuronal loss with subsequent striatal dopamine reduction, leading to motor deficits. Currently, there is no available effective therapy for PD; thus, novel therapeutic agents such as natural antioxidants with neuroprotective effects are emerging. Alpha-mangostin (αM) is a xanthone derivative compound from mangosteen peel with a cytoprotective effect depicted in neurodegenerative disease models. However, αM has low aqueous solubility and low biodistribution in the brain. Nanostructured lipid carriers (NLC) have been used to encapsulate bioactive compounds delivered to target organs to improve the oral bioavailability and effectiveness. This study aimed to investigate the effect of αM and αM encapsulated in NLC (αM-NLC) in mice with rotenone-induced PD-like neurodegeneration. Forty male ICR mice were divided into normal, PD, PD + αM, and PD + αM-NLC groups. Vehicle, αM (25 mg/kg/48 h), and αM-NLC (25 mg/kg/48 h) were orally administered, along with PD induction by intraperitoneal injection of rotenone (2.5 mg/kg/48 h) for 4 consecutive weeks. Motor abilities were assessed once a week using rotarod and hanging wire tests. Biochemical analysis of brain oxidative status was conducted, and neuronal populations in substantia nigra par compacta (SNc), striatum, and motor cortex were evaluated using Nissl staining. Tyrosine hydroxylase (TH) immunostaining of SNc and striatum was also evaluated. Results showed that rotenone significantly induced motor deficits concurrent with significant SNc, striatum, and motor cortex neuronal reduction and significantly decreased TH intensity in SNc (p < 0.05). The significant reduction of brain superoxide dismutase activity (p < 0.05) was also detected. Administrations of αM and αM-NLC significantly reduced motor deficits, prevented the reduction of TH intensity in SNc and striatum, and prevented the reduction of neurons in SNc (p < 0.05). Only αM-NLC significantly prevented the reduction of neurons in both striatum and motor cortex (p < 0.05). These were found concurrent with significantly reduced malondialdehyde level and increased catalase and superoxide dismutase activities (p < 0.05). Therefore, this study depicted the neuroprotective effect of αM and αM-NLC against rotenone-induced PD-like neurodegeneration in mice. We indicated an involvement of NLC, emphasizing the protective effect of αM against oxidative stress. Moreover, αM-NLC exhibited broad protection against rotenone-induced neurodegeneration that was not limited to nigrostriatal structures and emphasized the benefit of NLC in enhancing αM neuroprotective effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Available upon request.
References
Abdel-Salam OOE, Youness E, Khadrawy Y, Mohammed N, Sleem A (2014) Rotenone-induced nigrostriatal toxicity is reduced by methylene blue. J Neurorestoratol 2014:65–80
Badmus JA, Adedosu TO, Fatoki JO, Adegbite VA, Adaramoye OA, Odunola OA (2011) Lipid peroxidation inhibition and antiradical activities of some leaf fractions of Mangifera indica. Acta Pol Pharm 68(1):23–29
Balakrishnan R, Vijayraja D, Mohankumar T, Manimaran D, Ganesan P, Choi DK, Elangovan N (2021) Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson’s disease. J Chem Neuroanat 112:101890. https://doi.org/10.1016/j.jchemneu.2020.101890
Ball N, Teo W-P, Chandra S, Chapman J (2019) Parkinson’s Disease and the Environment. Frontiers in neurology 10:218–218. https://doi.org/10.3389/fneur.2019.00218
Beloqui A, Solinís M, Rodríguez-Gascón A, Almeida AJ, Préat V (2016) Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine 12(1):143–161. https://doi.org/10.1016/j.nano.2015.09.004
Buelna-Chontal M, Correa F, Hernández-Reséndiz S, Zazueta C, Pedraza-Chaverri J (2011) Protective effect of α-mangostin on cardiac reperfusion damage by attenuation of oxidative stress. J Med Food 14(11):1370–1374. https://doi.org/10.1089/jmf.2010.0238
Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis 34:279–290. https://doi.org/10.1016/j.nbd.2009.01.016
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909. https://doi.org/10.1016/s0896-6273(03)00568-3
De Maagd G, Philip A (2015) Parkinsons Disease and Its Management Part 1 Disease Entity Risk Factors Pathophysiology. Clin Present Diagnos P T a Peer Rev J Formula manage 40:504–532
Do HTT, Cho J (2020) Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer's Disease, Parkinson's Disease, and Depression with Pharmacokinetic and Safety Profiles. Int J Mol Sci 21. https://doi.org/10.3390/ijms21176211
Eleraky NE, Omar MM, Mahmoud HA, Abou-Taleb HA (2020) Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study. Pharmaceutics 14 12(5):451. https://doi.org/10.3390/pharmaceutics12050451
Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82(1):70–77. https://doi.org/10.1016/0003-9861(59)90090-6
Fang C, Al-Suwayeh S, Fang J-Y (2012) Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting. Recent Pat Nanotechnol 7(1):41–55. https://doi.org/10.2174/18722105130105
Fang Y, Su T, Qiu X, Mao P, Xu Y, Hu Z, Liu Q (2016) Protective effect of alpha-mangostin against oxidative stress induced-retinal cell death. Sci Rep 6:21018. https://doi.org/10.1038/srep21018
Ferrante RJ, Schulz JB, Kowall NW, Beal MF (1997) Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753:157–162. https://doi.org/10.1016/s0006-8993(97)00008-5
Ferris CF, Marella M, Smerkers B, Barchet TM, Gershman B, Matsuno-Yagi A, Yagi T (2013) A phenotypic model recapitulating the neuropathology of Parkinson’s disease. Brain Behav 3:351–366. https://doi.org/10.1002/brb3.138
Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, Chesselet MF (2004) Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 187:418–429. https://doi.org/10.1016/j.expneurol.2004.01.023
Hadwan MH, Abed HN (2016) Data supporting the spectrophotometric method for the estimation of catalase activity. Data Brief 6:194–199. https://doi.org/10.1016/j.dib.2015.12.012
Hao X-M, Li L-D, Duan C-L, Li Y-J (2017) Neuroprotective effect of α-mangostin on mitochondrial dysfunction and α-synuclein aggregation in rotenone-induced model of Parkinson’s disease in differentiated SH-SY5Y cells. J Asian Nat Prod Res 19:833–845. https://doi.org/10.1080/10286020.2017.1339349
Hassanzadeh P, Atyabi F, Dinarvand R, Dehpour A, Azhdarzadeh M, Dinarvand M (2017) Application of nanostructured lipid carriers: The prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway. Daru 25(1):25. https://doi.org/10.1186/s40199-017-0191-z
Hernando S, Herran E, Hernandez RM, Igartua M (2020) Nanostructured Lipid Carriers Made of Ω-3 Polyunsaturated Fatty Acids: In Vitro Evaluation of Emerging Nanocarriers to Treat Neurodegenerative Diseases. Pharmaceutics 12:928. https://doi.org/10.3390/pharmaceutics12100928
Höglinger GU, Féger J, Prigent A, Michel PP, Parain K, Champy P, Hirsch EC (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84:491–502. https://doi.org/10.1046/j.1471-4159.2003.01533.x
Ibrahim MY, Hashim NM, Mariod AA, Mohan S, Abdulla MA, Abdelwahab SI, Arbab IA (2016) α-Mangostin from Garcinia mangostana Linn: An updated review of its pharmacological properties. Arab J Chem 9:317–329. https://doi.org/10.1016/j.arabjc.2014.02.011
Janhom P, Dharmasaroja P (2015) Neuroprotective Effects of Alpha-Mangostin on MPP+-Induced Apoptotic Cell Death in Neuroblastoma SH-SY5Y Cells. J Toxicol 2015:919058. https://doi.org/10.1155/2015/919058
Johnson ME, Lim Y, Senthilkumaran M, Zhou XF, Bobrovskaya L (2015) Investigation of tyrosine hydroxylase and BDNF in a low-dose rotenone model of Parkinson’s disease. J Chem Neuroanat 70:33–41. https://doi.org/10.1016/j.jchemneu.2015.11.002
Joseph E, Saha R (2013) Advances in brain targeted drug delivery: Nanoparticulate systems. PharmaSciTech 3:1–8
Kumar V et al (2016) α-Mangostin Mediated Pharmacological Modulation of Hepatic Carbohydrate Metabolism in Diabetes Induced Wistar Rat. Beni-seuf univ J Appl Sci 5:255–276. https://doi.org/10.1016/j.bjbas.2016.07.001
Khosa A, Reddi S, Saha RN (2018) Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 103:598–613. https://doi.org/10.1016/j.biopha.2018.04.055
Lee CS, Sauer H, Bjorklund A (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 72:641–653. https://doi.org/10.1016/0306-4522(95)00571-4
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–75. https://doi.org/10.1016/S0021-9258(19)52451-6
Maiti P, Manna J, Dunbar GL (2017) Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl Neurodegener 6:28. https://doi.org/10.1186/s40035-017-0099-z
Mazzoni P, Shabbott B, Cortes J (2012) Motor Control Abnormalities in Parkinson’s Disease. Cold Spring Harb Perspect Med 2(6):a009282. https://doi.org/10.1101/cshperspect.a009282
Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247(10):3170–3175
Miyazaki I, Isooka N, Imafuku F, Sun J, Kikuoka R, Furukawa C, Asanuma M (2020) Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease. Int J Mol Sci 21. https://doi.org/10.3390/ijms21093254
Mythri R, Bharath M (2012) Curcumin: A Potential Neuroprotective Agent in Parkinson’s Disease. Curr Pharm Des 18:91–99. https://doi.org/10.2174/138161212798918995
Nava Catorce M, Acero G, Pedraza-Chaverri J, Fragoso G, Govezensky T, Gevorkian G (2016) Alpha-mangostin attenuates brain inflammation induced by peripheral lipopolysaccharide administration in C57BL/6J mice. J Neuroimmunol 297:20–27. https://doi.org/10.1016/j.jneuroim.2016.05.008
Parkhe A, Parekh P, Nalla L, Sharma N, Sharma M, Gadepalli A, Khairnar A (2019) Protective effect of alpha mangostin on rotenone induced toxicity in rat model of Parkinson’s disease. Neurosci Lett 716:134652
Pérez-Rojas JM, Cruz C, García-López P, Sánchez-González DJ, Martínez-Martínez CM, Ceballos G, Espinosa M, Meléndez-Zajgla J, Pedraza-Chaverri J (2009) Renoprotection by alpha-Mangostin is related to the attenuation in renal oxidative/nitrosative stress induced by cisplatin nephrotoxicity. Free Radic Res 43(11):1122–1132. https://doi.org/10.1080/10715760903214447
Rahimmi A, Khosrobakhsh F, Izadpanah E, Moloudi MR, Hassanzadeh K (2015) N-acetylcysteine prevents rotenone-induced Parkinson’s disease in rat: An investigation into the interaction of parkin and Drp1 proteins. Brain Res Bull 113:34–40. https://doi.org/10.1016/j.brainresbull.2015.02.007
Rangasamy SB, Dasarathi S, Pahan P, Jana M, Pahan K (2019) Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson’s Disease. J Neuroimmune Pharmacol 14:173–187. https://doi.org/10.1007/s11481-018-9808-3
Romuk EB, Szczurek W, Oleś M, Gabrysiak A, Skowron M, Nowak P, Birkner E (2017) The evaluation of the changes in enzymatic antioxidant reserves and lipid peroxidation in chosen parts of the brain in an animal model of Parkinson disease. Adv Clin Exp Med 26(6):953–959
Salvatore MF, McInnis TR, Cantu MA, Apple DM, Pruett BS (2019) Tyrosine Hydroxylase Inhibition in Substantia Nigra Decreases Movement Frequency. Mol Neurobiol 56:2728–2740. https://doi.org/10.1007/s12035-018-1256-9
Sampath PD, Vijayaraghavan K (2007) Cardioprotective effect of alpha-mangostin, a xanthone derivative from mangosteen on tissue defense system against isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol 21(6):336–339. https://doi.org/10.1002/jbt.20199
Soderstrom KE, Baum G, Kordower JH (2010) Animal Models of Parkinson's Disease Handbook of the Neuroscience of Aging:551–560 https://doi.org/10.1016/B978-008045046-9.00522-2
Sonia Angeline M, Chaterjee P, Anand K, Ambasta RK, Kumar P (2012) Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat. Neuroscience 220:291–301. https://doi.org/10.1016/j.neuroscience.2012.06.021
von Wrangel C, Schwabe K, John N, Krauss JK, Alam M (2015) The rotenone-induced rat model of Parkinson’s disease: behavioral and electrophysiological findings. Behav Brain Res 279:52–61
Wathoni N, Rusdin A, Motoyama K, Joni IM, Lesmana R, Muchtaridi M (2020) Nanoparticle Drug Delivery Systems for α-Mangostin. Nanotechnol Sci Appl 13:23–36. https://doi.org/10.2147/nsa.S243017
Weihe E, Depboylu C, Schütz B, Schäfer MK, Eiden LE (2006) Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression. Cell Mol Neurobiol 26:659–678. https://doi.org/10.1007/s10571-006-9053-9
Wu YN, Johnson SW (2009) Rotenone reduces Mg2+-dependent block of NMDA currents in substantia nigra dopamine neurons. Neurotoxicol 30(2):320–5. https://doi.org/10.1016/j.neuro.2009.01.002
Yao L, Gu X, Song Q, Wang X, Huang M, Hu M, Gao X (2016) Nanoformulated alpha-mangostin ameliorates Alzheimer’s disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance. J Control Release 226:1–14. https://doi.org/10.1016/j.jconrel.2016.01.055
Yeung PKK, Lai AKW, Son HJ, Zhang X, Hwang O, Chung SSM, Chung SK (2017) Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson’s disease. Neurobiol Aging 50:119–133. https://doi.org/10.1016/j.neurobiolaging.2016.11.008
Yostawonkul J, Surassmo S, Namdee K, Khongkow M, Boonthum C, Pagseesing S, Yata T (2017) Nanocarrier-mediated delivery of α-mangostin for non-surgical castration of male animals. Scientific Reports 7. https://doi.org/10.1038/s41598-017-16563-3
Zhang Q-S, Heng Y, Mou Z, Huang J-Y, Yuan Y-H, Chen N-H (2017) Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease. Acta pharmacologica Sinica 38. https://doi.org/10.1038/aps.2017.49
Zhang Y, Guo H, Guo X, Ge D, Shi Y, Lu X, Zhang Q (2019) Involvement of Akt/mTOR in the Neurotoxicity of Rotenone-Induced Parkinson’s Disease Models. Int J Environ Res Public Health 16:3811. https://doi.org/10.1038/aps.2017.49
Acknowledgements
We thank the Department of Zoology and the Faculty of Science, Kasetsart University and Science Achievement Scholarship of Thailand.
Funding
This study was funded by Department of Zoology and the Faculty of Science (Student Research Project), Kasetsart University, and Science Achievement Scholarship of Thailand.
Author information
Authors and Affiliations
Contributions
Wachiryah Thong-asa and Romgase Sakamula are equally conceived and designed research, analyzed data and wrote the manuscript. All authors read and approved the manuscript for publication.
Corresponding author
Ethics declarations
Ethics approval
All applicable international and national guidelines for the care and use of animals were followed.
Consent to participate
All authors agree to participate.
Consent for publication
All authors agree to publish.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sakamula, R., Yata, T. & Thong-asa, W. Nanostructure lipid carriers enhance alpha-mangostin neuroprotective efficacy in mice with rotenone-induced neurodegeneration. Metab Brain Dis 37, 1465–1476 (2022). https://doi.org/10.1007/s11011-022-00967-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-022-00967-w